Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The use of nonhuman primate models in HIV vaccine development.

Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L.

PLoS Med. 2008 Aug 12;5(8):e173. doi: 10.1371/journal.pmed.0050173. No abstract available.

2.

Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.

Staprans SI, Feinberg MB, Shiver JW, Casimiro DR.

Curr Opin HIV AIDS. 2010 Sep;5(5):377-85. doi: 10.1097/COH.0b013e32833d2e19. Review.

PMID:
20978377
3.

The role of nonhuman primates in the development of an AIDS vaccine.

Nathanson N, Hirsch VM, Mathieson BJ.

AIDS. 1999;13 Suppl A:S113-20. Review.

PMID:
10885770
4.

HIV/AIDS vaccines: a need for new concepts?

Girard MP, Bansal GP.

Int Rev Immunol. 2008;27(6):447-71. doi: 10.1080/08830180802432160. Review.

PMID:
19065351
5.

Non-human primate models for AIDS vaccines.

Desrosiers RC.

AIDS. 1995;9 Suppl A:S137-41. Review. No abstract available.

PMID:
8819580
6.

Reproductive/developmental toxicity and immunotoxicity assessment in the nonhuman primate model.

Buse E, Habermann G, Osterburg I, Korte R, Weinbauer GF.

Toxicology. 2003 Apr 1;185(3):221-7. Review.

PMID:
12581697
7.

HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?

Uberla K.

PLoS Pathog. 2008 Aug 29;4(8):e1000114. doi: 10.1371/journal.ppat.1000114. Review. No abstract available.

8.

Moving candidate vaccines into development from research: lessons from HIV.

Sullivan M.

Immunol Cell Biol. 2009 Jul;87(5):366-70. doi: 10.1038/icb.2009.30. Epub 2009 May 12. Review.

PMID:
19434070
9.

Primate models for HIV vaccines.

Schultz AM, Hu SL.

AIDS. 1993;7 Suppl 1:S161-70. Review. No abstract available.

PMID:
8363780
10.

Nonhuman primates are relevant models for research in hematology, immunology and virology.

Hérodin F, Thullier P, Garin D, Drouet M.

Eur Cytokine Netw. 2005 Jun;16(2):104-16. Review.

11.

Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development.

Baroncelli S, Negri DR, Michelini Z, Cara A.

Expert Rev Vaccines. 2008 Nov;7(9):1419-34. doi: 10.1586/14760584.7.9.1419. Review.

PMID:
18980543
12.

HIV-1/AIDS vaccine development: are we in the darkness.

Qiu C, Xu JQ.

Chin Med J (Engl). 2008 May 20;121(10):939-45. Review. No abstract available.

PMID:
18706210
13.

Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.

Belyakov IM, Ahlers JD.

Trends Immunol. 2008 Nov;29(11):574-85. doi: 10.1016/j.it.2008.07.010. Review.

PMID:
18838298
14.

AIDS in african nonhuman primate hosts of SIVs: a new paradigm of SIV infection.

Pandrea I, Silvestri G, Apetrei C.

Curr HIV Res. 2009 Jan;7(1):57-72. Review.

PMID:
19149555
15.

Social and behavioral science in HIV vaccine trials: a gap assessment of the literature.

Lau CY, Stansbury JP, Gust DA, Kafaar Z.

Expert Rev Vaccines. 2009 Feb;8(2):179-90. doi: 10.1586/14760584.8.2.179. Review.

PMID:
19196198
16.

IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment.

Leone A, Picker LJ, Sodora DL.

Curr HIV Res. 2009 Jan;7(1):83-90. Review.

PMID:
19149557
17.

Use of predictive markers of HIV disease progression in vaccine trials.

Gurunathan S, Habib RE, Baglyos L, Meric C, Plotkin S, Dodet B, Corey L, Tartaglia J.

Vaccine. 2009 Mar 23;27(14):1997-2015. doi: 10.1016/j.vaccine.2009.01.039. Epub 2009 Feb 4. Review.

PMID:
19200450
18.

Strategies for optimizing targeting and delivery of mucosal HIV vaccines.

Ahlers JD, Belyakov IM.

Eur J Immunol. 2009 Oct;39(10):2657-69. doi: 10.1002/eji.200939269. Review.

19.

Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2009 Jun;15(6):263-74. doi: 10.1016/j.molmed.2009.04.003. Epub 2009 May 30. Review.

PMID:
19487159
20.

New approaches to prediction of immune responses to therapeutic proteins during preclinical development.

Perry LC, Jones TD, Baker MP.

Drugs R D. 2008;9(6):385-96. doi: 10.2165/0126839-200809060-00004. Review.

PMID:
18989990

Supplemental Content

Support Center